Level of mutant KRAS EVs in plasma even correlated with response to therapy and tumor burden with pancreatic cancer (Kahlert et al., 2014; Allenson et al., 2017; Yang S. et al., 2017; Bernard et al., 2019). Here, KRAS is linked to familial pancreatic carcinoma.